Authors

Serialization 2.0: Why It’s Time to Upgrade, and What’s at Stake

This serialization system represents a business imperative that yields significant competitive advantages.

Rethinking Medicare Price Negotiations: Innovation, Insurance Reform, and Patient Access

In the final part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, argues that while Medicare price controls may reduce federal spending, they have yet to meaningfully improve patient access—contending that true reform must address insurance design, out-of-pocket costs, and the long-term impact on life sciences innovation and investment.

Navigating the Landscape of Global AI Governance

The importance of embracing universal values and business models that prioritize humanity.

The Ways Pharma Leaders are Rewiring their Organizations for Launch Success

HTI-4 Standards Target Lack of Transparency in Medication Access

In the final part of his Pharma Commerce video interview, Colin Banas, MD, DrFirst’s chief medical officer, explains how amid soaring patient and provider frustration, new HTI-4 standards are rapidly forcing change across the insurance and technology sectors to solve the current "transparency problem," making the status of a life-saving prescription as clear and actionable as tracking a takeout order.

Community Pharmacies in Crisis: Navigating the Challenges and Closures

With today's pharmacy landscape shaken by unprecedented and wider disruption to healthcare support and delivery, community and independent entities strive to remain an integral cog in the mix.

How Rare Disease Therapies Evolved Into a Strategic Growth Engine for Biopharma

Rare disease drugs now drive innovation, investment, and portfolio strategy as policy incentives, scientific advances, and market success reshape biopharmaceutical growth.

Navigating Access and Reimbursement Through Uncertainty

A forum intended for HCPs, policy experts, and industry leaders addresses pressing obstacles facing this sector of the industry today.

Working with the Middle

How pharma can productively coexist with PBMs—and still lower drug costs faster.

Why Your EHR Messaging Must Be Real-Time

This first-party approach to data-driven messaging can ensure timely, compliant, and personalized engagement with healthcare providers at the point of care.

The Prominence of Pharmacy Deserts

How chain and local closures are impacting healthcare access.

Quality and Compliance in the Pharmaceutical Industry: Navigating a Transformed Landscape

Rising recalls, tighter FDA enforcement, global supply chain dependencies, and rapid technology shifts are reshaping pharmaceutical quality and compliance—forcing manufacturers to rethink oversight, resilience, and continuous improvement across operations.

Why Direct-to-Patient Is the Pharma Industry’s Next Power Move

How direct-to-patient programming can transform the prescription journey for patients and manufacturers alike.

Your Guide to Outsourcing Critical Sample Management

Discover how to evaluate the true costs and considerations of internal vs. outsourced sample storage.

Pharmaceutical Logistics: Finding Shipping Solutions that Match Your Level of Precision and Care (May 2026)

This eBook highlights Werner’s premium and expedited shipping solutions designed specifically to address the high-stakes requirements of the $1.6 trillion global pharmaceutical industry. It details how their specialized multimodal services—including 24/7 dedicated operational teams and experienced driver networks—mitigate risks for high-value, perishable and time-sensitive medical freight.

Addressing Polypharmacy Challenges in Europe with Real World Evidence

A multi-national study reveals over half of older adults in several European countries are prescribed five or more medications—spotlighting the urgent need for better data-driven prescribing strategies.

Q&A: Why Pharma Supply Chains Are Turning to AI

4flow's Natalia Andreyeva breaks down the persistent planning failures driving AI adoption in pharma supply chains.

How DSCSA Compliance Is Unlocking Recall Efficiency

In the final part of his Pharma Commerce video interview, Dan Walles, VP & GM, traceability and compliance solutions, TraceLink, notes that while DSCSA was designed for compliance, its first major business value is enabling targeted recalls.

HDA 2025 Traceability Seminar: DSCSA Compliance Ushers in a More Secure and Transparent Pharma Supply Chain

Kala Shankle, JD, HDA’s vice president of regulatory affairs, shares that as DSCSA traceability requirements take full effect, distributors and trading partners are preparing for long-term gains in supply chain security, recall efficiency, and counterfeit prevention.

Omnichannel, Evolved: Redefining the Model for Modern Pharma Marketing

Pharma must align data, personalization, and cross-functional orchestration to deliver human-centered experiences that connect with patients, HCPs, and caregivers alike.

Building Agility and Adaptability Into Pharma Operations

Why driving results from such strategies—amid industry disruption—will be critical to success.

The Competitive Edge in Pharma Logistics: Sustainability, Safety, and Precision Delivery

Why the U.S. Pharmaceutical Cold Chain Is Poised for Innovation

Understanding distribution models through prescription capture patterns

This insight piece breaks down how three different specialty pharmacy network structures relate to prescription capture patterns in medically integrated dispensing settings. You’ll learn what distinguishes each type of limited distribution model, how those differences are seen in internal vs. external dispensing behavior, and what the data suggests about the way prescriptions flow across networks. It’s designed to help teams better understand distribution models and think more clearly about how network design may shape dispensing dynamics.

A New Chapter

Congress Revives Push to Digitize Prescription Information

New bipartisan legislation would give the FDA authority to modernize prescribing information, reducing waste while improving accuracy and patient care.

2025 Pharma Forecast: Four Pivotal Trends Revolutionizing Market Access Strategies

From Policy to Patients: Bridging the Medicare Part D Disconnect

While the Inflation Reduction Act introduces a $2,100 out-of-pocket cap and payment smoothing options for Medicare Part D beneficiaries, low awareness and persistent health literacy gaps threaten to limit their real-world impact—highlighting the need for coordinated action across providers, pharmacies, industry, and advocacy groups.